MetaCap

OS Therapies Incorporated (OSTX)

NYSE: OSTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.803-0.0174 (-2.12%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OSTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$42.00M
EPS (TTM)
-$1.08
52-week range
0.58 – 2.25
Day range
0.7901 – 0.8625
Volume / Avg
489.73K / 722.66K
Beta
—

52-week range

$0.58$2.25

OSTX stock today

OS Therapies (OSTX) closed at $0.803 on Nov 20, down 2.12% (-$0.0174), versus the S&P 500's 3.70% decline. At this level, OSTX sits near the bottom of its 52-week range of $0.58 to $2.25: 64.3% below the high, set on Jun 29, 2026 and 38.4% above the low. OSTX is down 42.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 53.0%.

OS Therapies has posted a net loss over the last twelve months (EPS of -$1.08), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About OS Therapies

Company profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Paul A. Romness M.P.H.
Headquarters
Grasonville, MD
Employees
4
IPO year
2024

Financial highlights

Full financials

OS Therapies reported a net loss of $28.8 million, compared with a loss of $8.9 million a year earlier. Diluted earnings per share came in at -$0.98.

OS Therapies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023
Revenue———
Growth———
Net income$-28.75M$-8.88M$-7.79M
EPS (diluted)$-0.98$-1.28$-1.46

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$8.50+958.53%

  • Strong buy 1
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $6.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.23 vs $-0.13
Surprise
-76.92%

OSTX news

All OSTX news

OS Therapies peers

Health Care sector
OSTX peer companies
CompanyPrice% ChgMarket capCompare
INCRIntercure Ltd.3.24-7.69%$42.03Mvs OSTX
BMEABiomea Fusion Inc.0.5744-2.38%$41.75Mvs OSTX
CRBPCorbus Pharmaceuticals Holdings Inc.2.06-15.40%$42.45Mvs OSTX
MREOMereo BioPharma Group plc ADR0.26-5.45%$41.52Mvs OSTX
ELTXElicio Therapeutics Inc.1.45-3.33%$41.05Mvs OSTX
TLPHTalphera Inc.0.7852+6.25%$40.80Mvs OSTX
SPROSpero Therapeutics Inc.0.742-10.20%$43.23Mvs OSTX
RLYBRallybio Corporation15.47-0.32%$43.32Mvs OSTX

Indexes, lists and sector

OS Therapies stock FAQ

What is OS Therapies's stock price today?

OSTX last traded at $0.803 as of Nov 20, 4:00 PM EST, down 2.12% on the day. Prices are delayed at least 15 minutes.

Who is OS Therapies's CEO?

Mr. Paul A. Romness M.P.H. is the chief executive officer of OS Therapies Incorporated, which has about 4 employees.

What is the OSTX 52-week high?

The 52-week high for OSTX is $2.25 and the 52-week low is $0.58. The stock is currently 64.3% below its high.

Compare OSTX